ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Feasibility and Long Term Safety of T Regulatory Cell Therapy in Kidney Transplantation

P. N. Harden1, D. Game2, J. Van der Net1, F. Issa3, W. Petchey1, M. Brook1, P. Friend1, R. Hilton4, G. Lombardi5, K. Wood3

1Kidney Transplantation, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 2Kidney Transplantation, Guys and St Thomas's Hospital, London, United Kingdom, 3Transplant Immunology Research Group, Oxford University, Oxford, United Kingdom, 4Kidney Transplantation, Guys and St Thomas's Hospital, Oxford, United Kingdom, 5Transplant Immunology Group, Kings Healthcare Partners, London, United Kingdom

Meeting: 2020 American Transplant Congress

Abstract number: LB-7

Keywords: Graft survival, Immunosuppression, Kidney transplantation, T cells

Session Information

Session Name: Late Breaking Oral Abstract

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: A sequential clinical trial of autologous polyclonal T regulatory cellular therapy compared with a standardised reference cohort of live donor kidney transplant recipients. The objective was to demonstrate feasibility, safety, risk of rejection and potential minimisation of immunosuppression in the T regulatory cell therapy treated cohort.

*Methods: Living donor transplant recipients receiving their first kidney transplant with moderate sensitisation status (PRA<40%) were recruited in 2 sequential clinical trials to form an initial reference and subsequent cell therapy cohort. All received immunosuppression with Mycophenolate mofetil (MMF), Tacrolimus and tapered steroids. Induction therapy with Basiliximab was only used in the reference group. Polyclonal T regulatory cells were isolated from 350ml of whole blood from transplant recipients in the cell therapy group 4-6 weeks before transplantation and expanded in culture in a dose escalation format to produce 1 -10 x106 cells per kg for infusion at Day 5 post-transplantation. Recipients had a protocol biopsy at month 7 and the opportunity of MMF withdrawal. Follow up was continued for 4 years.

*Results: 19[median age 46(31-57) yrs; 74% male; 79% white] transplant recipients in the reference group and 12[median age 44(28-69) yrs; 92% male; 83% white] in the cell therapy group. Similar HLA mismatches in both groups: 1-2 mismatches 47% v 42%; 3-4 mismatches 42% v 50%; 5-6 mismatches 11% v8 % reference v cell therapy groups. Patient and Transplant survival 100% in both groups; acute rejection free survival at 1 and 4 years post transplant respectively 84% v 100% and 78.9% v 100% in reference and cell therapy groups. There were no adverse reactions related to T regulatory cell infusions and reduced BK virus and CMV infection rates in the cell therapy cohort. Four patients in the cell therapy group had MMF withdrawn at 7 months post transplant and remain rejection free on Tacrolimus monotherapy 4 years post transplant.

*Conclusions: This study demonstrates the safety of infusion of autologous polyclonal T regulatory cells as an adjuvant to immunosuppressive therapy in kidney transplantation. The reduced incidence of viral infection and absence of malignancy during the extended follow-up to 4 years post cell infusion is very reassuring. Successful transplantation without induction therapy and tapering to monotherapy with Tacolimus in 33% of the T regulatory cell therapy group is a potentially promising means of immunosuppression minimalisation and requires testing in large randomised clinical trials

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Harden PN, Game D, Net JVander, Issa F, Petchey W, Brook M, Friend P, Hilton R, Lombardi G, Wood K. Feasibility and Long Term Safety of T Regulatory Cell Therapy in Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/feasibility-and-long-term-safety-of-t-regulatory-cell-therapy-in-kidney-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences